OncoOne is a biotech company dedicated to the development of innovative therapeutics for patients with solid tumors and limited treatment options. OncoOne was founded to advance multiple proprietary drug modalities targeting oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory factor (MIF) and an exciting new drug target in solid tumor indications. The founders have a long history in pharmaceutical drug development and oncology research. OncoOne aims to rapidly enter clinical trials in pancreatic, colorectal, lung and ovarian cancer, which represent solid tumor indications with high unmet medical need and significant market potential.
Although still an early-stage startup company, OncoOne has established supportive alliances with scientific advisors and CROs. Furthermore, the company has built a remarkable laboratory capacity with an outstanding group of scientists and lab technicians and is constantly looking for new talents to grow the team. OncoOne has established a strong patent portfolio with additional IP in preparation.